Drug-independent models that link biomarker response to clinical end points are critical to support early (end of phase II) clinical decisions. In oncology, change in tumor size (a biomarker of drug effect evaluated in phase II) is linked to survival (a phase III end point) in some solid tumors.
2009 年 08 月 1 日
Author(s): Rene Bruno, Laurent Claret
Year: 2009 年 08 月 1 日